^
Association details:
| Biomarker: | IDH2 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + eftozanermin alfa (ABBV-621) (TRAIL R2 agonist, TRAIL R1 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-In-Human Study of a Trail Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma
Published date:
09/14/2020
Excerpt:
In this phase 1 study, adults with relapsed/refractory (RR) acute myeloid leukemia (AML) or diffuse large B-cell lymphoma (DLBCL)...In 63% of patients with RR AML...molecular aberrations were observed, with IDH1/2 and RAS being the most frequently mutated genes....Antitumor activity was observed in patients with AML treated with eftoza-VEN...
